Key sentence from the paper: “[A]dding docetaxel and estramustine to ADT significantly improved recurrence-free survival compared with ADT alone in patients with high-risk localized prostate cancer, with no apparent long-term toxicity related to chemotherapy.”

Key sentence from the paper: “[P]atients who receive ≥ 8 doses of GnRH agonists and life expectancy of ≥ 5 years were at a significantly higher risk of [sudden cardiac death].”

Key sentence from the paper: “[T]he combination of standard ADT and six cycles of docetaxel resulted in significantly longer overall survival than that with standard ADT alone in men with hormone-sensitive metastatic prostate cancer.”

Key sentence from the paper: “ADT is associated with a higher risk of other cause mortality in patients with PCa. This harmful association was most evident in healthier patients, and those with long-term ADT use.”

Key sentence from the paper: “[S]trength training had beneficial effects on muscle cellular outcomes in PCa patients on ADT and is therefore recommended.”

Key sentence from the paper: “…The historic T [testosterone] target for ADT of ≤ 50 ng/dl is too high, given that surgical castration results in T levels < 20 ng/dl, and significant improvements in clinical outcomes for patients meeting lower serum T thresholds have been demonstrated.”

Key sentence from the paper: “More fit patients…are less at risk [of cardiovascular disease], and [this] supports the view that those patients on ADT with preesxisting cardiovascular disease may be at a greater risk.” 

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. By Gonzalez et al. 2015 

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. By Harshman et al. 2015

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture. By Wilson et al. 2015